[go: up one dir, main page]

MX2017014768A - Composiciones anticonceptivas y metodos para mejorar la eficacia y modulacion de los efectos secundarios. - Google Patents

Composiciones anticonceptivas y metodos para mejorar la eficacia y modulacion de los efectos secundarios.

Info

Publication number
MX2017014768A
MX2017014768A MX2017014768A MX2017014768A MX2017014768A MX 2017014768 A MX2017014768 A MX 2017014768A MX 2017014768 A MX2017014768 A MX 2017014768A MX 2017014768 A MX2017014768 A MX 2017014768A MX 2017014768 A MX2017014768 A MX 2017014768A
Authority
MX
Mexico
Prior art keywords
methods
compositions
progestin
shbg
effectiveness
Prior art date
Application number
MX2017014768A
Other languages
English (en)
Inventor
Macfarlane Katie
E Kafrissen Michael
Kydonieus Agis
Original Assignee
Agile Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agile Therapeutics Inc filed Critical Agile Therapeutics Inc
Publication of MX2017014768A publication Critical patent/MX2017014768A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se divulgan composiciones y métodos para la administración de hormonas progestina que tienen afinidad de unión por la globulina de unión a la hormona sexual (SHBG). Las composiciones combinan dichas progestinas con ligandos de SHBG no de progestina para desplazar al menos parte de la progestina de la SHBG en el plasma sanguíneo, aumentando de esta forma su biodisponibilidad. También se divulgan métodos para modular los niveles de progestina y estrógenos e la sangre mediante el uso de la unión a SHBG y desplazamiento, para optimizar la eficacia de formulaciones anticonceptivas y minimizar los efectos secundarios y los eventos adversos.
MX2017014768A 2015-05-18 2016-05-18 Composiciones anticonceptivas y metodos para mejorar la eficacia y modulacion de los efectos secundarios. MX2017014768A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562163113P 2015-05-18 2015-05-18
US201562254999P 2015-11-13 2015-11-13
PCT/US2016/033024 WO2016187269A1 (en) 2015-05-18 2016-05-18 Contraceptive compositions and methods for improved efficacy and modulation of side effects

Publications (1)

Publication Number Publication Date
MX2017014768A true MX2017014768A (es) 2018-03-23

Family

ID=56116539

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014768A MX2017014768A (es) 2015-05-18 2016-05-18 Composiciones anticonceptivas y metodos para mejorar la eficacia y modulacion de los efectos secundarios.

Country Status (10)

Country Link
US (3) US20180125860A1 (es)
EP (1) EP3297634A1 (es)
JP (2) JP2018515552A (es)
CN (1) CN107995864A (es)
AU (2) AU2016264137B2 (es)
BR (1) BR112017024783A2 (es)
CA (1) CA2986039A1 (es)
HK (1) HK1251938A1 (es)
MX (1) MX2017014768A (es)
WO (1) WO2016187269A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
HUE054551T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Ösztetrolt tartalmazó, szájban diszpergálódó tabletta
MA44205B1 (fr) 2015-06-18 2021-04-30 Estetra Sprl Comprimé orodispersible comprenant estetrol
SMT201800232T1 (it) 2015-06-18 2018-07-17 Mithra Pharmaceuticals S A Unita' di dosaggio orodispersibile contenente un componente di estetrolo
EP3310333B1 (en) 2015-06-18 2020-04-29 Estetra SPRL Orodispersible dosage unit containing an estetrol component
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
WO2018170005A1 (en) * 2017-03-15 2018-09-20 Agile Therapeutics, Inc. Personalized contraceptive formulations
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
IE61236B1 (en) * 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women
US4863738A (en) 1987-11-23 1989-09-05 Alza Corporation Skin permeation enhancer compositions using glycerol monooleate
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
MX9301121A (es) * 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
US7704983B1 (en) * 1992-03-02 2010-04-27 Eastern Virginia Medical School Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
PT836506E (pt) 1995-06-07 2003-04-30 Ortho Mcneil Pharm Inc Penso transdermico para administracao de 17-desacetil norgestimato so ou em combinacao com um estrogenio
US6139873A (en) * 1996-07-10 2000-10-31 Cedars-Sinai Medical Center Combined pharmaceutical estrogen-androgen-progestin
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US6251956B1 (en) * 1998-08-20 2001-06-26 Ortho Pharmaceutical Corporation Combination progestin oral contraceptive regimen
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US7384650B2 (en) * 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
US7045145B1 (en) * 1999-11-24 2006-05-16 Agile Therapeutics, Inc. Transdermal contraceptive delivery system and process
EP1242012B1 (en) * 1999-11-24 2009-12-30 Agile Therapeutics, Inc. Improved transdermal contraceptive delivery system and process
EP1325752A3 (en) 2000-08-03 2003-08-06 Antares Pharma IPL AG Composition for transdermal and/or transmucosal administration of active compounds which ensures adequate therapeutic levels
JP4965263B2 (ja) * 2003-12-12 2012-07-04 バイエル ファーマ アクチエンゲゼルシャフト 浸透増強剤を必要としないホルモンの経皮送達
CN1672685A (zh) * 2004-03-26 2005-09-28 董可娟 一种新的避孕药物
US20100178323A1 (en) * 2007-07-10 2010-07-15 Agis Kydonieus Dermal Delivery Device
PL2214643T3 (pl) * 2007-11-02 2014-09-30 Acrux Dds Pty Ltd Układ transdermalnego dostarczania hormonów i steroidów
CA2740002C (en) * 2008-10-08 2016-11-01 Agile Therapeutics, Inc. Transdermal delivery
WO2010042610A1 (en) * 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
CA2740005C (en) * 2008-10-08 2016-11-01 Agile Therapeutics, Inc. Transdermal delivery
EP2410859A4 (en) * 2009-03-27 2013-03-13 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
HK1204287A1 (en) * 2012-01-27 2015-11-13 敏捷治疗公司 Transdermal hormone delivery
WO2014100599A1 (en) * 2012-12-21 2014-06-26 Teikoku Pharma Usa, Inc. Compositions and methods for transdermal delivery of hormones and other medicinal agents

Also Published As

Publication number Publication date
AU2016264137B2 (en) 2021-08-19
US20250319102A1 (en) 2025-10-16
HK1251938A1 (zh) 2019-05-03
US20240156838A1 (en) 2024-05-16
CN107995864A (zh) 2018-05-04
AU2021262853A1 (en) 2021-12-02
JP2018515552A (ja) 2018-06-14
WO2016187269A1 (en) 2016-11-24
EP3297634A1 (en) 2018-03-28
CA2986039A1 (en) 2016-11-24
AU2021262853B2 (en) 2024-05-09
AU2016264137A1 (en) 2018-01-18
BR112017024783A2 (pt) 2018-08-07
US20180125860A1 (en) 2018-05-10
JP2021169503A (ja) 2021-10-28

Similar Documents

Publication Publication Date Title
MX2017014768A (es) Composiciones anticonceptivas y metodos para mejorar la eficacia y modulacion de los efectos secundarios.
MX2019008208A (es) Métodos para tratar el cáncer con anticuerpos anti-tim-3.
CL2016001809A1 (es) Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x (divisional sol. n° 3344-15).
NI201700173A (es) Anticonceptivos a base de drospirenona para paciente femenina afectada con exceso de peso
BR112015023391A2 (pt) formulações compreendendo conjugado droga-anticorpo anti-egfr
MX2018012486A (es) Composiciones para aplicacion topica de compuestos.
MX392606B (es) Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina.
MX2018002462A (es) Una composicion farmaceutica para reducir la grasa localizada y sus usos.
MY188749A (en) Compositions comprising a combination of nivolumab and ipilimumab
MX2018001723A (es) Conjugados farmaco-multiligando y usos de los mismos.
BR112016029338A2 (pt) creme transdérmico
BR112014031910A2 (pt) formulações e terapias naturais de combinação para reposição hormonal
MX2018011706A (es) Composicion farmaceutica de hormona esteroide.
CR20190433A (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
PE20211588A1 (es) Compuestos y sus usos para aliviar sintomas asociados a la menopausia
CL2017001840A1 (es) Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para preparar y usar las mismas.
ES2948324R1 (es) Proceso para preparar (15alfa,16alfa,17beta)-estra-1,3,5(10)-trieno-3,15,16,17-tetrol monohidrato (Estetrol monohidrato)
MX2019003685A (es) Composicion farmaceutica para uso en el tratamiento terapeutico del cancer y complicaciones del cancer.
AR095691A1 (es) FORMULACIÓN DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca), PROCEDIMIENTO, USO
CL2019000174A1 (es) Composición vaginal que comprende una combinación de estrógeno y vitamina d.
CO2017001918A2 (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
CL2018001653A1 (es) Concentrados en emulsión de compuestos lipofílicos
MX2017013879A (es) Composiciones que comprenden anakinra.
BR112014018426A8 (pt) Composição e dispositivo para administração transdérmica, e, método para administrar uma progestina
BR112018012616A2 (pt) formulação galênica que compreende um fármaco tópico